We know that medical information can be challenging to navigate. That’s why we’re focusing on making our information more clear, concise and understandable to help people make informed health decisions. Learn more: http://merck.us/4hYjBLW
About us
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ
- Website
-
http://merck.us/2J2xAUh
External link for Merck
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Rahway, New Jersey
- Type
- Public Company
- Specialties
- Pharmaceutical
Locations
-
Primary
Get directions
126 E Lincoln Ave
P.O. Box 2000
Rahway, New Jersey 07065, US
-
Get directions
351 N Sumneytown Pike
North Wales, PA 19454, US
Employees at Merck
Updates
-
Our scientists are working to discover and develop medicines for Alzheimer’s disease and other debilitating neurodegenerative disorders, which continue to represent one of the greatest therapeutic challenges of our time. Learn more about our research in Alzheimer’s disease: http://merck.us/4cVKQWj
-
Today, we announced new data from our Phase 3 trial in pulmonary arterial hypertension (#PAH) at #ACC25. Learn more about our latest cardiovascular update: http://merck.us/4jwxGld
-
We’re excited to share pivotal Phase 3 data for our investigational subcutaneous #immunotherapy currently under regulatory review in the U.S. and Europe. These findings are being presented today at #ELCC2025. Read more about our latest news: http://merck.us/4iIS2r8
-
-
Today’s EC decision represents a significant milestone to help protect against invasive #pneumococcal disease and pneumococcal #pneumonia. Read more: http://merck.us/3E4YHNf
-
Today, we announced an exclusive license to develop, manufacture and commercialize an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Atherosclerotic cardiovascular disease (#ASCVD) remains the leading cause of morbidity and death around the world. We have a long history of making an impact in #cardiovasculardisease and this agreement will expand and complement our diverse cardio-metabolic pipeline. Learn more: http://merck.us/4kZRmPL
-
-
Thank you to The Wall Street Journal for again including us on its list of the 250 Best-Managed Companies – this time for 2024. Being recognized among such an esteemed group underscores our ongoing commitment to excellence and responsible leadership. We’re proud of the work our team continues to do in support of our purpose, as we remain focused on making a positive impact for patients and all who depend on us.
-
We’re looking forward to sharing new research aimed at improving outcomes for people living with #cardiovascular disease at #ACC25. Learn more: http://merck.us/4iUFQDq
-
We’re making an impact beyond the lab by mentoring the next generation of innovators, including our inspiring #WomenInScience. This Women’s History Month, hear advice from some of our scientists about succeeding in #STEM.
-
Today we shared our latest research on an investigational antiretroviral therapy for adults living with HIV at #CROI2025. Learn more about the results from two Phase 3 trials: http://merck.us/43FzWS8
Affiliated pages
Similar pages
Browse jobs
Stock
MRK
NYSE
20 minutes delay
$81.47
-4.92 (-5.695%)
- Open
- 86.12
- Low
- 81.08
- High
- 86.27
Data from Refinitiv
See more info on